Tragara sees peachy Capoxigem future even as APRiCOT trial fails overall in NSCLC
This article was originally published in Scrip
Executive Summary
San Diego-based Tragara Pharmaceuticals is focusing on positive data from a subset of patients after a Phase II trial investigating its oral once-daily COX-2 inhibitor, Capoxigem (apricoxib; TG01), in combination with erlotinib in patients with non-small cell lung cancer (NSCLC) failed to meet the primary endpoint in the overall study population.